Alexion Pharmaceuticals Inc. (ALXN) Release: Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients With PNH and aHUS at American Society of Hematology Annual Meeting
11/7/2012 10:29:55 AM
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers will present data from clinical studies of Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders, at the 54th Annual Meeting of the American Society of Hematology (ASH). Abstracts summarizing these data are published on the ASH website and can be accessed using the links below. The ASH annual meeting will be held December 8-11, 2012, at the Georgia World Congress Center in Atlanta.